Get the Stockscreener App
1.72
1.18%
0.02
In 8 Bio Inc stock is traded at $1.72, with a volume of 27,191.
It is up +1.18% in the last 24 hours and down -13.57% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$1.70
Open:
$1.67
24h Volume:
27,191
Relative Volume:
0.11
Market Cap:
$16.80M
Revenue:
-
Net Income/Loss:
$-20.66M
P/E Ratio:
-0.3658
EPS:
-4.7022
Net Cash Flow:
$-14.63M
1W Performance:
+10.97%
1M Performance:
-13.57%
6M Performance:
-22.35%
1Y Performance:
-77.95%
1-Day Range:
$1.60
$1.748
1-Week Range:
$1.5901
$1.81
52-Week Range:
$1.17
$8.241
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.72 | 16.60M | 0 | -20.66M | -14.63M | -4.7022 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
IBTROZI launch lifts Nuvation Bio (NUVB) 2025 revenue while losses narrow - Stock Titan
683 Capital reports 5.23% stake in Gossamer Bio | GOSS SEC FilingForm SCHEDULE 13G - Stock Titan
INmune Bio (NASDAQ: INMB) outlines RDEB and Alzheimer’s trial paths - Stock Titan
BOLD SEC FilingsBOUNDLESS BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
TRML SEC FilingsTourmaline Bio 10-K, 10-Q, 8-K Forms - Stock Titan
TELA SEC FilingsTela Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Reduction | GOSS Stock News - GuruFocus
BioMarin’s top execs schedule four investor events in March - Stock Titan
Construction giant brings drug tests in-house with fingerprint scans at UK sites - Stock Titan
BIO-key to secure Mozambique digital payments for 36.6M people - Stock Titan
Axsome Therapeutics, Inc. SEC 10-K Report - TradingView
BioMarin (BMRN) grows 2025 revenue 13% and guides 2026 EPS to $4.95–$5.15 - Stock Titan
Inclement weather delays PROCEPT BioRobotics Q4 call, Investor Day - Stock Titan
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Gossamer Bio reports PROSERA topline: missed primary 6MWD endpoint but secondary endpoints and high-risk subgroup favored seralutinib - TradingView
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - Business Wire
Zura Bio (ZURA) appoints Mark Eisner and Ajay Nirula to its board - Stock Titan
Sartorius 2025 results summarized in Bio-Rad (NYSE: BIO) update - Stock Titan
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
CORDStrom Phase III RDEB data to be detailed by INmune Bio (NASDAQ: INMB) - Stock Titan
Biotech Passage Bio lines up Oppenheimer and TD Cowen investor talks - Stock Titan
Point72, Steven A. Cohen disclose 9.9% stake in Q32 Bio (QTTB) - Stock Titan
Q32 Bio (NASDAQ: QTTB) raises $10.5M to fund alopecia trials - Stock Titan
Darwin Global discloses 8.1% Belite Bio (BLTE) holding in 13G/A - Stock Titan
Inmune Bio Inc Advances CORDStrom and XPro1595 Regulatory Pathways - TradingView
[SCHEDULE 13G/A] GRI Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
Annovis Bio, Inc. Secures DSMB Approval for Phase 3 Trial - TradingView
BioXcel (NASDAQ: BTAI) updates IGALMI at-home treatment opportunity - Stock Titan
Upstream Bio posts mid-stage asthma trial win (UPB:NASDAQ) - Seeking Alpha
Upstream Bio, Inc. Reports Positive Phase 2 VALIANT Trial Results for Verekitug - TradingView
Severe asthma trial: experimental drug cuts attacks up to 56% - Stock Titan
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma - The Manila Times
What’s the outlook for Third Harmonic Bio Inc.’s sectorWeekly Trade Review & Entry Point Confirmation Alerts - mfd.ru
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer - GlobeNewswire Inc.
Avant Technologies (AVAI) changes its name to Avaí Bio, Inc. - Stock Titan
KALA BIO (KALA) names director Avi Minkowitz CEO and CFO as David Lazar steps down - Stock Titan
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewswire
Biotech Climb Bio to field questions at Guggenheim, Oppenheimer, Leerink events - stocktitan.net
KYNB SEC FilingsKYNTRA BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
GRI Bio Reiterates Full Year 2025 Financial Results, - GlobeNewswire
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
KALA BIO Signs Securities Purchase Agreement With Series AAA Investors - TradingView
Tevogen Bio Holdings Inc Evaluates Special Cash Dividend - TradingView
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance
GRI Bio (GRI) expands at-the-market equity program to $60M capacity - Stock Titan
Annovis Bio, Inc. Announces Progress in Alzheimer's and Parkinson's Trials - TradingView
GRI Bio, Inc. Announces Positive Phase 2a Clinical Trial Data for GRI-0621 - TradingView
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.71%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):